Skip to main content

Wealthfront Reports Fiscal Third Quarter 2026 Results with Record Total Revenue of $93.2 Million and Net Income of $30.9 Million

Revenue up 16% to a record $93.2 millionNet income of $30.9 million with a Net income margin of 33% Total Platform Assets up 21% to a record $92.8 billionAdjusted EBITDA1 up 24% to $43.8 million with an Adjusted EBITDA margin1 of 47% PALO ALTO, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Wealthfront Corporation (Nasdaq: WLTH), a tech-driven financial platform helping digital natives turn their savings into wealth, announced financial results for its fiscal third quarter ended October 31, 2025. David Fortunato – CEO, President & Director: “We continued to execute in our core business driving Platform Assets to a record at quarter-end amidst a dynamic macro environment. This included the best quarter in net cross account transfers from Cash Management to Investment Advisory in the company’s history. We achieved this while...

Continue reading

Technip Energies announces dates for full-year 2025 results and 2026 quarterly results

Technip Energies announces dates for full-year 2025 results and 2026 quarterly results Technip Energies (PARIS:TE) today announces the planned dates for the release of its financial results for full-year 2025 and quarterly results for 2026. The company will publish its results on its website at investors.technipenergies.com on the following dates:FY 2025 Results: February 26, 2026 Q1 2026 Results: April 30, 2026 H1 2026 Results: July 30, 2026 9M 2026 Results: October 29, 2026Financial results will be published at approximately 7:30 a.m. (CET) on the dates listed above and will be accessible through a press release on the company’s website www.ten.com Each announcement will be accompanied by a presentation for investors and analysts, followed by a webcast/conference call hosted by management. Details for accessing these events will...

Continue reading

INTEGRATED MULTI-THREAT HEADBORNE SYSTEM PROTOTYPE TO BE FUNDED AND DEVELOPED FOR U.S. ARMY BY TEAM WENDY CERADYNE AND THEON INTERNATIONAL

Press Release Under a U.S. Army-funded initiative, Team Wendy Ceradyne and Theon International partner to develop an Integrated Multi-Threat Headborne System (IMHS) prototype set to enhance soldier protection and situational awareness.  Bloomberg (THEON:NA) / Reuters (THEON.AS) Salem, New Hampshire – January 12th, 2026. Team Wendy Ceradyne, a leading US-based developer and manufacturer of advanced combat helmets for the Department of Defense, and Theon International Plc (THEON), a global company specializing in electro-optical systems including night vision, thermal imaging, and augmented reality (AR) technologies, have announced a strategic partnership under a US Army Combat Capabilities Development Command (DEVCOM) Soldier Center (SC)-funded initiative. Together, the companies are developing a next generation Integrated Multi-Threat...

Continue reading

Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

Appoints Medical Technology Veteran Karen N. Prange to Board of Directors SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) — Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 ResultsRevenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024. Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more than 3 million cumulative treatments on Tablo. Year-end cash, including...

Continue reading

Sify reports Consolidated Financial Results for Q3 FY 2025-26

Revenues of INR 11596 Million. EBITDA of INR 2470 Million. Loss for the period INR 329 Million. CHENNAI, India, Jan. 12, 2026 (GLOBE NEWSWIRE) — DETAILS OF EARNING CALL         January 13, 2026 | 8:30 AM ET | 07:00 PM IST Participant Dial in: To join: +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International) | Access Code: 910873 On the call: Mr. Raju Vegesna, Chairman of the Board and Mr. M P Vijay Kumar, Executive Director & Group CFO Live webcast: https://www.webcaster4.com/Webcast/Page/2184/53449. Archives: +1-877-481-4010 (Toll Free in the U.S. or Canada) or +1-919-882-2331 (International). Passcode 53449 Replay is available until January 20, 2026. HIGHLIGHTSRevenue was INR 11596 Million, an increase of 11% over the same quarter last year. EBITDA was INR 2470 Million, an increase of...

Continue reading

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance. The Company expects to report fourth quarter and full year 2025 revenues of approximately $30.5 million and $109 million, respectively, representing year-over-year growth of 23% and 21%, respectively. During the fourth quarter, the Company billed 11,201 tissue-based units and 27,486 liquid-based units, representing year-over-year growth of (5%) and 128%, respectively, reflecting Q4 focus on integration of the Exosome...

Continue reading

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024. MRD revenue for the fourth quarter and full year 2025 was approximately $62 million and $212 million, representing an increase of 54% and 46%, respectively, over the corresponding periods in 2024. Excluding...

Continue reading

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 ResultsTotal revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17% Achieved positive cash flow in the fourth quarter Sold 15,800 Cyclo G6® probes compared to 13,300 in the prior year quarter Sold 44 Cyclo G6 Glaucoma...

Continue reading

Viridien : Full-year 2025 financial update

Paris (France), January 12, 2026 Full-year 2025 financial updateRobust activity, with segment revenue expected to exceed $1,150 million, including more than $440 million in Geoscience (+10% year-on-year) and more than $400 million in Earth DataSolid cash flow generation above $130 million, resulting in Net Cash Flow for 2025 exceeding $100 million after repayment of the $28 million asset-backed facility related to the Group’s HPC infrastructureBond repayments totaling $97 million, fully utilizing the 10% annual optional redemption clause included in the bond documentationNet debt (pre-IFRS 16) expected to stand around $750 million at year-endSophie Zurquiyah, Chair and CEO of Viridien: “2025 marked another important milestone in the execution of our asset-light strategy and financial roadmap. We delivered solid operational performance...

Continue reading

Global Mofy Announces Fiscal Year 2025 Financial Results; Conference Call Scheduled for Friday, January 9th, at 8:30 AM Eastern Time

Total Revenue of $55.9 million, up 35.3% year-over-year, marking a new record high in the Company’s history. Gross Profit of $22.5 million, reflecting continued investment in AI-native production capabilities. NON-GAAP Operating Income reached $10.8 million, representing a year-over-year increase of 17.9%. Strategic transition toward AI-native production and AI Agent–driven workflows accelerated during fiscal year 2025.BEIJING, Jan. 09, 2026 (GLOBE NEWSWIRE) — Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced its financial results for the fiscal year ended September 30, 2025. During fiscal year 2025, the Company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.